A Phase I Study of XH-S003 in Healthy Volunteers - Trial NCT06272747
Access comprehensive clinical trial information for NCT06272747 through Pure Global AI's free database. This Phase 1 trial is sponsored by S-Infinity Pharmaceuticals Co., Ltd and is currently Not yet recruiting. The study focuses on Healthy Adults. Target enrollment is 44 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
S-Infinity Pharmaceuticals Co., Ltd
Timeline & Enrollment
Phase 1
Feb 22, 2024
Oct 30, 2024
Primary Outcome
Number of participants with adverse events (AEs),Number of participants with adverse events (AEs)
Summary
The purpose of the study is to assess the safety, tolerability and pharmacokinetics of
 XH-S003 in healthy volunteers under SAD (Single ascending dose) and MAD (Multiple ascending
 dose) studies. In addition, this study evaluates the food effects of XH-S003.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06272747
Non-Device Trial